Adverse events across generations of bone-modifying agents in patients with solid tumor cancers reported in Phase III randomized trials.
暂无分享,去创建一个
Liying Zhang | H. Lam | M. Poon | E. Chow | U. Emmenegger | Michelle Zhou | N. Lao | E. Wong | F. Mok | K. Li